Norverapamil is a calcium channel blocker. It is the main active metabolite of verapamil. It contributes significantly to the therapeutic effects of verapamil, which include the treatment of hypertension, angina, and arrhythmias. Despite being a metabolite of verapamil, norverapamil retains much of the pharmacological activity of verapamil, particularly impacting the calcium ion flow through L-type calcium channels, leading to its therapeutic cardiovascular and vasodilation effects.
via PubMed
Norverapamil is a calcium channel blocker. It is the main active metabolite of verapamil. It contributes significantly to the therapeutic effects of verapamil, which include the treatment of hypertension, angina, and arrhythmias. Despite being a metabolite of verapamil, norverapamil retains much of the pharmacological activity of verapamil, particularly impacting the calcium ion flow through L-type calcium channels, leading to its therapeutic cardiovascular and vasodilation effects.
== Pharmacodynamics == Norverapamil inhibits L-type calcium channels located in the heart and blood vessels, leading to several pharmacological effects including vasodilation, negative inotropy, and negative dromotropy. Norverapamil relaxes the smooth muscles of blood vessels, reducing systemic vascular resistance and consequently lowering blood pressure. Also, by decreasing calcium influx into heart muscle cells, it is able to lower myocardial contractility. This makes it useful in reducing the workload of the heart, particularly in cardiovascular conditions such as angina. Norverapamil is also able to slow atrioventricular (AV) conduction, which is useful in controlling supra-ventricular arrhythmias by controlling the heart rate through reduced electrical conduction.
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).